title: External radiation therapy of prostatic carcinoma and its relationship to hormonal therapy.
abstract: From 1980 to 1990, a total of 54 patients with prostatic carcinoma were treated with external radiation therapy at the Kumamoto National Hospital. Ten patients were classified as Stage B, 22 as Stage C, and another 22 as Stage D according to the American Urological Association Clinical Staging System. The 5-year survival for all 54 patients was 30%. The 5-year disease-specific survival was 67% for Stage B, 47% for Stage C, and 26% for Stage D. The 5-year survival was 43% for patients in whom radiation therapy was initiated immediately after the first diagnosis or with less than one year of hormonal therapy, while it was 0% for patients in whom radiation therapy was initiated after more than one year of hormonal therapy (p = 0.01). The cause of intercurrent death was acute myocardial infarction in four patients and acute cardiac failure in one. Four of these patients received hormonal therapy for more than one year. The incidence of radiation-induced proctitis was not severe. This study suggests that long-term hormonal therapy prior to radiation therapy worsens the prognosis of patients with prostatic carcinoma.
authors.affiliation: Department of Radiology, Kumamoto National Hospital, Yatsushiro, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Takada
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: J
authors.initials: J
authors.lastname: Nishi
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Hatanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Baba
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D002303:Cardiac Output, Low / Q000209:etiology; D002423:Cause of Death; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D004961:Estramustine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D009367:Neoplasm Staging; D011349:Proctitis / Q000209:etiology; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D004961:Estramustine; D004054:Diethylstilbestrol; C004955:fosfestrol